Subsequent analysis of immunofluorescence and Western blotting revealed that the administration of etrolizumab resulted in increased activation of microglia/macrophages and astrocytes, as evidenced by Iba-1 and GFAP staining, surrounding the hematoma 3 d after ICH (Figures 7A-B). This evidence concerns the gene GFAP and hematoma.